Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Statins for primary prevention

Aaron M. Tejani, Vijaya Musini, Ken Bassett, Colin Dormuth, Tom Perry and James M. Wright
CMAJ April 17, 2012 184 (7) 791; DOI: https://doi.org/10.1503/cmaj.112-2036
Aaron M. Tejani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijaya Musini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Bassett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Dormuth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Perry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Wright
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

We wish to address an important issue that relates to the analysis of serious adverse events in the systematic review of statins for primary prevention by Tonelli and colleagues.1

In the results section, the authors indicate “… the pooled risk of serious adverse events did not differ significantly between treatment groups (RR 1.01, 95% CI 0.96–1.07; I2 = 8%).” Although we congratulate the authors for obtaining data on serious adverse events from 21 of 29 trials, we urge them to post the forest plot and raw data from this analysis on CMAJ’s website for use by other researchers. The pooled relative risk confirms the finding of the Therapeutics Initiative of the University of British Columbia, that total serious adverse events are not reduced by statins in the clinical setting of primary prevention.2,3 The Therapeutics Initiative concluded that statins do not have a proven net health benefit in primary prevention. The analysis by Tonelli and colleagues, which furnishes data on serious adverse events from more trials, strengthens that conclusion.

What does the estimate of relative risk for serious adverse events reported by Tonelli and colleagues mean in clinical terms? The RR of 1.01 implies that taking a statin increases the chance of dying, being admitted to hospital or being permanently disabled by a nonsignificant 1% as compared with placebo. A conservative assumption is that serious adverse events in those trials were more frequent in the statin group than in the placebo group.

Why do Tonelli and colleagues ignore the serious adverse events outcome in their conclusions? Perhaps the data create a dilemma for proponents of widespread statin use in primary prevention. How can statins cause a statistically significant reduction in all-cause mortality, nonfatal myocardial infarction and nonfatal stroke — all outcomes that represent serious adverse events and that should be counted as such within the data on serious adverse events reported in clinical trials — and yet not reduce total serious adverse events? This implies that statins increase the risk of other serious adverse events to negate the decreased risk in cardiovascular morbidity and mortality.

In summary, we consider that the most important finding in the meta-analysis by Tonelli and colleagues is that statins do not reduce total serious adverse events and thus do not provide a net health benefit in primary prevention.

References

    1. Tonelli M,
    2. Lloyd A,
    3. Clement F,
    4. et al.
    for the Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis CMAJ 2011;183: E1189–1202.
  1. Do statins have a role in primary prevention? Therapeutics Letter 2003;48:1–2. Available: www.ti.ubc.ca/newsletter/do-statins-have-role-primary-prevention (accessed 2011 Dec. 13 2011).
  2. Do statins have a role in primary prevention? An update. Therapeutics Letter 2010;77:1–2. Available: www.ti.ubc.ca/letter77 (accessed 2011 Dec. 12).

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire